Page last updated: 2024-12-05

pyrithiamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyrithiamine: A thiamine antagonist due to its inhibition of thiamine pyrophosphorylation. It is used to produce thiamine deficiency. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrithiamine : A pyridinium ion that is 3-(2-hydroxyethyl)-2-methylpyridine substituted at position 1 by a (4-amino-2-methylpyrimidin-5-yl)methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10802
SCHEMBL ID94765
MeSH IDM0018263

Synonyms (37)

Synonym
nsc76271
nsc-76271
unii-5jb3029bj7
5jb3029bj7 ,
pyridinium, bromide, monohydrobromide
nsc400971
pyrithiamin
nsc-400971
534-64-5
2-picolinium, bromide, monohydrobromide
pyrithiamine bromide hydrobromide
pyrithiamine hydrobromide
neopyrithiamine
pyrithiamine
2-picolinium, 1-((4-amino-2-methyl-5-pyrimidinyl)methyl)-3-(2-hydroxyethyl)-,bromide, monohydrobromide
1-(4-ammonio-2-methylpyrimidin-5-yl)-3-(2-hydroxyethyl)-2-methylpyridinium dibromide
pyridinium, 1-((4-amino-2-methyl-5-pyrimidinyl)methyl)-3-(2-hydroxyethyl)-2-methyl-, bromide, monohydrobromide
nsc 400971
einecs 208-604-8
pyrithiamine hydrobromide, ~95%, crystalline
pyrithiamin hydrobromide
FT-0603456
SCHEMBL94765
pyrithiamine [mi]
1-(2-methyl-4-amino-5-pyrimidyl)methyl-2-methyl-3-hydroxyethylpyridinium bromide hydrobromide
1-((4-amino-2-methyl-5-pyrimidinyl)methyl)-3-(2-hydroxyethyl)-2-methylpyridinium bromide hydrobromide (1:1:1)
neopyrithiaminehydrobromide
neopyrithiamine hydrobromide
1-((4-amino-2-methylpyrimidin-5-yl)methyl)-3-(2-hydroxyethyl)-2-methylpyridinium bromide hydrobromide
2-[1-[(4-amino-2-methylpyrimidin-5-yl)methyl]-2-methylpyridin-1-ium-3-yl]ethanol;bromide;hydrobromide
1-((4-amino-2-methylpyrimidin-5-yl)methyl)-3-(2-hydroxyethyl)-2-methylpyridin-1-ium bromide hydrobromide
DTXSID80968058
pyrithiamine (hydrobromide)
Q27262418
STARBLD0009627
AS-81706
AKOS040755537

Research Excerpts

Overview

Pyrithiamine is an inhibitor of thiamine metabolism that induces neurological symptoms similar to that of Wernicke-Korsakoff Syndrome in animals.

ExcerptReferenceRelevance
"Pyrithiamine is an inhibitor of thiamine metabolism that induces neurological symptoms similar to that of Wernicke-Korsakoff Syndrome in animals."( Pyrithiamine as a substrate for thiamine pyrophosphokinase.
Hurley, TD; Liu, JY; Timm, DE, 2006
)
2.5

Treatment

Pyrithiamine treatment in low thiamine medium (M199) for 7 days caused cytotoxic effects on RBE4 cells at all concentrations (10-50 microg/ml) Treatment resulted in loss of righting reflex, convulsions and more widespread neuropathological damage compared to that observed followingThiamine deprivation.

ExcerptReferenceRelevance
"Pyrithiamine treatment and diet-induced TD impaired the memory of wild-type mice, but had little effect on APP/PS1 mice."( Exposure to pyrithiamine increases β-amyloid accumulation, Tau hyperphosphorylation, and glycogen synthase kinase-3 activity in the brain.
Chen, J; Dong, W; Gu, F; Pan, X; Sun, X; Yu, Z; Zhao, J; Zhao, L; Zhong, C, 2011
)
1.47
"Pyrithiamine-treated slices showed both lower basal and veratridine-stimulated respiration rates compared to control slices."( Effect of pyrithiamine treatment on potassium ion fluxes in rat cortical slices.
Brosemer, RW; Gale, JM, 1984
)
1.39
"Pyrithiamine treatment in low thiamine medium (M199) for 7 days caused cytotoxic effects on RBE4 cells at all concentrations (10-50 microg/ml)."( Metabolic and permeability changes caused by thiamine deficiency in immortalized rat brain microvessel endothelial cells.
Abbott, NJ; Aleshaiker, A; Rist, RJ; Romero, IA, 1997
)
1.02
"Pyrithiamine treated animals demonstrated impaired retention of a 24 h recall of passive avoidance."( Long-lasting changes in regional brain amino acids and monoamines in recovered pyrithiamine treated rats.
Anderson, CD; Langlais, PJ; Mair, RG; McEntee, WJ, 1988
)
1.22
"The pyrithiamine-treated rats produced by our method histopathologically exhibited the edematous lesion not only around the third ventricle and at the tegmentum of pons, as expected, but also in the cerebral cortex. "( Metabolic studies of the edematous cerebral cortex of the pyrithiamine-treated thiamine-deficient rat.
Nakazawa, S; Shimura, T; Takahashi, H; Yoshino, Y, 1988
)
1.08
"Pyrithiamine treatment results, within 3 weeks, in loss of righting reflex, convulsions and more widespread neuropathological damage compared to that observed following thiamine deprivation."( Activities of thiamine-dependent enzymes in two experimental models of thiamine deficiency encephalopathy: 3. Transketolase.
Butterworth, RF; Giguère, JF, 1987
)
0.99
"Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats at loss of righting reflexes."( Selective down-regulation of the astrocyte glutamate transporters GLT-1 and GLAST within the medial thalamus in experimental Wernicke's encephalopathy.
Butterworth, RF; Danbolt, NC; Hazell, AS; Pow, DV; Rao, KV, 2001
)
0.65

Toxicity

ExcerptReferenceRelevance
" We show that the toxic effect of this drug is relieved by low concentrations of thiamine (Th) and that the pyrimidine moiety of the Th molecule is responsible for growth inhibition release."( Amiloride toxicity in the fission yeast Schizosaccharomyces pombe is released by thiamine and mutations in the thiamine-repressible gene car1.
Edenharter, E; Fankhauser, H; Niederberger, C; Schweingruber, ME, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (205)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990108 (52.68)18.7374
1990's35 (17.07)18.2507
2000's33 (16.10)29.6817
2010's25 (12.20)24.3611
2020's4 (1.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.95 (24.57)
Research Supply Index5.39 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other214 (97.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]